Home » Newsletters » BioWorld Science

BioWorld Science

Dec. 15, 2000

View Archived Issues

Gilead cleared to test adefovir dipivoxil for HBV in the clinic in China

Ligocyte licenses M cell vaccine technology from Montana State University

NeoGenesis and Merck & Co. enter collaborative research agreement

Alliance completes enrollment in phase II/III trial of LiquiVent

Diversa and Glaxo Wellcome establish drug discovery alliance

Arakis and Penwest combine expertise to develop novel chronotherapeutic product for RA

Ivax licenses cladribine for MS

Acquisition of Megan Health by Avant finalized

Developments at Alexion during first quarter

FDA requests additional data to support Dynepo BLA

Schering-Plough seeks FDA approval for new formulations of desloratadine

Genmab moves HuMax-CD4 for RA to phase II

Praecis seeks FDA approval of abarelix depot for prostate cancer

Carborane-based retinoid receptor antagonists presented at recent scientific meeting

Structurally novel nucleosides reported to be highly active against MDR HIV strains

Synthesis and biological activity of nonacylguanidine NHE inhibitors

TRK-851: clinical trials under way for selective DOP antagonist with antitussive activity

Genetic Therapy constructs promising new antiangiogenic gene therapy

Maxamine fails to convince ODAC as treatment for advanced metastatic melanoma

FDA advisory committee recommends Campath for CLL

New progesterone receptor modulators continue to emerge from AHP/Ligand alliance

ODAC unanimously recommends approval of Femara as first-line breast cancer treatment

Potent, long-acting, orally active M3 antagonist selected for clinical development at Banyu

Novel Aventis compounds for cardiovascular disorders interact with angiotensin receptors

Recent patent covers selective COX-2 inhibitors synthesized at Merck Frosst

Potential new contraceptive agents patented by Schering

More PARP inhibitors identified at BASF

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 27, 2026.
Detecting the invisible: minimal residual disease at AACR 2026
BioWorld Science
Minimal residual disease (MRD) has become a central concept in modern oncology, reshaping how clinicians evaluate response, relapse risk and treatment precision....
A free gene therapy? Regeneron’s Otarmeni approved for hearing loss
BioWorld
Children and adults with a type of congenital hearing loss now have a free treatment option, with the U.S. FDA’s accelerated approval of Regeneron Pharmaceuticals...
AACR 2026: The age of agentic AI in oncology
BioWorld Science
New Approach Methodologies (NAMs) for drug development are transforming biomedical research by replacing or complementing animal models. More than 90% of...
Sichuan Kelun Pharmaceutical Research Institute discovers GPR6 inverse agonists
BioWorld Science
Sichuan Kelun Pharmaceutical Research Institute Co. Ltd. has identified G protein-coupled receptor 6 (GPR6) inverse agonists reported to be useful for the...